Difficult-to-treat rheumatoid arthritis affects up to 28 percent of patients who fail to achieve lasting remission. Researchers at Semmelweis University published findings in Nature Reviews Rheumatology and The Lancet Rheumatology showing that persistent symptoms may stem from comorbid conditions like obesity, smoking, sleep disorders, and depression rather than ongoing inflammation alone.
The limits of standard antirheumatic therapy
Most patients with rheumatoid arthritis respond well to treatment. However, between 6 and 28 percent of patients fall into a difficult-to-treat category. According to research from Semmelweis University, these cases often persist because secondary health problems maintain physical symptoms.
When inflammatory markers normalize under standard treat-to-target protocols but pain and fatigue continue, doctors frequently increase medication doses. Researchers argue this approach can be counterproductive if inflammation is no longer the primary driver of discomfort.
How lifestyle and mood trap the body in pain
Chronic pain and depression interact directly with physical functioning. These conditions reduce daily physical activity, contribute to weight gain, and disrupt restorative sleep.
That disruption worsens mood and amplifies pain perception, creating a self-sustaining cycle that standard antirheumatic drugs cannot break on their own. Smoking and obesity introduce additional systemic stressors that complicate recovery and blunt treatment efficacy.
Dr. György Nagy on rethinking clinical strategy
Dr. György Nagy, head of the Department of Rheumatology and Immunology at Semmelweis University, explained the shift in clinical reasoning.
“When target values improve but the patient still suffers from pain and fatigue, it is worth taking a step back. In such cases, instead of automatically prescribing more medication, doctors should look for what is maintaining the symptoms – whether it is chronic pain syndrome, depression, sleep disorders, or obesity,” Dr. Nagy stated.
The clinical model developed by the Semmelweis team treats standard disease-activity tracking as an early warning system. If measurable inflammation drops while subjective symptoms remain elevated, clinicians use that discrepancy to screen for psychiatric, lifestyle, or sleep-related comorbidities.
Global citations and artificial intelligence integration
The conceptual framework established by Semmelweis researchers has gained wide international recognition. Publications defining difficult-to-treat rheumatic disease have accumulated more than a thousand citations across global literature, influencing treatment guidelines beyond rheumatoid arthritis alone.
Looking ahead, the research team is integrating artificial intelligence into their workflow. Dr. Lilla Gunkl-Tóth, a PhD student at Semmelweis University and first author of the publications, outlined the next phase of development.
“With AI-based pattern recognition, we could identify subgroups among patients, and with the help of these data we could create more effective, almost personalized treatment strategies for them,” Dr. Gunkl-Tóth said.